[go: up one dir, main page]

MX2019005723A - Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo. - Google Patents

Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.

Info

Publication number
MX2019005723A
MX2019005723A MX2019005723A MX2019005723A MX2019005723A MX 2019005723 A MX2019005723 A MX 2019005723A MX 2019005723 A MX2019005723 A MX 2019005723A MX 2019005723 A MX2019005723 A MX 2019005723A MX 2019005723 A MX2019005723 A MX 2019005723A
Authority
MX
Mexico
Prior art keywords
fgfr4
inhibitor
preparing
growth factor
factor receptor
Prior art date
Application number
MX2019005723A
Other languages
English (en)
Other versions
MX389403B (es
Inventor
Zhang Yang
Liu Xing
Hu Guoping
Chen Xiaoxin
Chen Shuhui
Li Jian
Liu Zhuowei
Long Chaofeng
Chen Zhengxia
Wang Yikai
Dai Meibi
Zhao Haixia
Original Assignee
Guangdong Zhongsheng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Zhongsheng Pharmaceutical Co Ltd filed Critical Guangdong Zhongsheng Pharmaceutical Co Ltd
Publication of MX2019005723A publication Critical patent/MX2019005723A/es
Publication of MX389403B publication Critical patent/MX389403B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una clase de compuestos como se muestra en la fórmula (I) como inhibidores de FGFR4 y sales farmacéuticamente aceptables de los mismos, métodos de preparación de los mismos y el uso de los mismos en la preparación de fármacos para tratar enfermedades relacionadas con FGFR4.(ver formula).
MX2019005723A 2016-11-17 2017-11-17 Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo MX389403B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611012431 2016-11-17
PCT/CN2017/111634 WO2018090973A1 (zh) 2016-11-17 2017-11-17 Fgfr4抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
MX2019005723A true MX2019005723A (es) 2019-10-21
MX389403B MX389403B (es) 2025-03-20

Family

ID=62145242

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005723A MX389403B (es) 2016-11-17 2017-11-17 Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo

Country Status (12)

Country Link
US (1) US11008292B2 (es)
EP (1) EP3543227B1 (es)
JP (1) JP7063899B2 (es)
KR (1) KR102249632B1 (es)
CN (1) CN109952290B (es)
AU (1) AU2017359819B2 (es)
CA (1) CA3043948C (es)
IL (1) IL266659B (es)
MX (1) MX389403B (es)
NZ (1) NZ754218A (es)
WO (1) WO2018090973A1 (es)
ZA (1) ZA201903845B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018361264B2 (en) * 2017-11-01 2021-04-01 Guangdong Xianqiang Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
CN102731485B (zh) * 2011-04-02 2016-06-15 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
CN104540809B (zh) 2012-07-11 2018-12-11 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
WO2014139145A1 (en) * 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
PT3057943T (pt) * 2013-10-18 2018-07-24 Eisai R&D Man Co Ltd Inibidores de fgfr4 pirimidina
WO2016115412A1 (en) * 2015-01-18 2016-07-21 Newave Pharmaceutical Llc Dual-warhead covalent inhibitors of fgfr-4
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
JP6431622B2 (ja) 2015-04-14 2018-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 結晶性ｆｇｆｒ４阻害剤化合物およびその使用
AU2018361264B2 (en) * 2017-11-01 2021-04-01 Guangdong Xianqiang Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof

Also Published As

Publication number Publication date
US20200062716A1 (en) 2020-02-27
KR102249632B1 (ko) 2021-05-10
MX389403B (es) 2025-03-20
NZ754218A (en) 2021-07-30
AU2017359819B2 (en) 2020-05-28
CA3043948C (en) 2021-08-31
CN109952290A (zh) 2019-06-28
CN109952290B (zh) 2022-05-03
CA3043948A1 (en) 2018-05-24
KR20190077085A (ko) 2019-07-02
ZA201903845B (en) 2020-12-23
US11008292B2 (en) 2021-05-18
WO2018090973A1 (zh) 2018-05-24
IL266659A (en) 2019-07-31
IL266659B (en) 2022-01-01
JP2019537613A (ja) 2019-12-26
EP3543227B1 (en) 2020-12-30
JP7063899B2 (ja) 2022-05-09
EP3543227A1 (en) 2019-09-25
EP3543227A4 (en) 2019-10-30
AU2017359819A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
MX392230B (es) Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurogenerativos.
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
BR112016008849B8 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2020002168A (es) Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidérmico.
MX389672B (es) Inhibidores de ssao de aminopirimidina
MX382166B (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
EA202193015A1 (ru) Ингибиторы cdk
EA201792214A1 (ru) Соединения замещенного хиназолина
MX381994B (es) Inhibidor de janus quinasa.
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
EA201692487A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
JOP20190174A1 (ar) مثبطات jak1 انتقائية
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
EA201790921A1 (ru) Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
NZ752587A (en) Lsd1 inhibitors and medical uses thereof